153 NEO-PTC-01 (BNT-221), an autologous neoantigen-specific T-cell product for adoptive cell therapy of metastatic melanoma

• Michael Nelson,
• Divya Lenkala,
• Jessica Kohler,
• Brian McCarthy,
• Jonathan McGee,
• Daniel Kallin,
• Janani Sridar,
• Paul Turcott,
• Dewi Harjanto,
• Cynthia Nijenhuis,
• Joost Van Den Berg,
• Richard Gaynor,
• Marit Van Buuren

Affiliations

Michael Nelson

Centre for Epidemiology and Evidence, New South Wales Ministry of Health, Sydney, New South Wales, Australia

Divya Lenkala

1BioNTech US Inc., Cambridge, MA, USA

Jessica Kohler

1BioNTech US Inc., Cambridge, MA, USA

Brian McCarthy

1BioNTech US Inc., Cambridge, MA, USA

Jonathan McGee

1BioNTech US Inc., Cambridge, MA, USA

Daniel Kallin

1BioNTech US Inc., Cambridge, MA, USA

Janani Sridar

1BioNTech US Inc., Cambridge, MA, USA

Paul Turcott

1BioNTech US Inc., Cambridge, MA, USA

Dewi Harjanto

1BioNTech US Inc., Cambridge, MA, USA

Cynthia Nijenhuis

2Netherlands Cancer Institute, Cambridge, MA, USA

Joost Van Den Berg

2Netherlands Cancer Institute, Cambridge, MA, USA

Richard Gaynor

1BioNTech US Inc., Cambridge, MA, USA

Marit Van Buuren

1BioNTech US Inc., Cambridge, MA, USA